James E. Flynn - 17 Nov 2023 Form 4 Insider Report for CareMax, Inc.

Reporting relationship: Director, Director by Deputization, 10%+ Owner
Issuer ticker: N/A
Reported as of: 17 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Nov 2023, 18:09:00 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 01 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for CareMax, Inc. on 21 Nov 2023.

Key facts

This page summarizes James E. Flynn's Form 4 filing for CareMax, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Nov 2023, 18:09.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CMAX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +12,123
Change %
Price
Shares after: 12,123
Date: 17 Nov 2023
Ownership: Through Deerfield Management Company, L.P.
Footnotes: F1, F2, F3, F4

CMAX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 15,811,090
Date: 17 Nov 2023
Ownership: Through Deerfield Partners, L.P.
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMAX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -12,123
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2023
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Class A Common Stock
Underlying amount: 12,123
Exercise price
Footnotes: F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported transaction involved the vesting and settlement of 12,123 restricted stock units ("RSUs") on November 17, 2023. On such date, each such RSU vested in full and converted into Class A common stock of the Issuer on a one-for-one basis.

Footnote F2

Kevin Berg, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The RSUs granted to Mr. Berg were held for the benefit, and at the direction, of Deerfield Management.

Footnote F3

This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management and of the general partner of Deerfield Partners, L.P. Deerfield Management is the investment manager of Deerfield Partners, L.P. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Footnote F4

In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by Deerfield Management and Deerfield Partners is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Footnote F5

Each RSU was awarded on November 17, 2022, vested on November 17, 2023 and represented a contingent right to receive one share of the Issuer's Class A common stock in accordance with the Issuer's 2021 Long-Term Incentive Plan.

SEC remarks

Kevin Berg, an employee of Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.